Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Eisen, T Marais, R Affolter, A Lorigan, Paul C Robert, C Corrie, P Ottensmeier, C Chevreau, C Chao, D Nathan, P D
Eisen, T
Marais, R
Affolter, A
Lorigan, Paul C
Robert, C
Corrie, P
Ottensmeier, C
Chevreau, C
Chao, D
Nathan, P D
Citations
Altmetric:
Abstract
The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I dose-escalation study and the activity of the combination was explored in an open-label phase II study.
Description
Date
2011-07-26
Publisher
Collections
Keywords
Type
Article
Citation
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. 2011, 105 (3):353-9 Br. J. Cancer